Abstract

Objective: The presence of bone and bone marrow (BM) metastases in neuroblastoma patients are independent adverse prognostic factors, so precise and consistent definitions of both categories on imaging are important. The objectives of this systematic review were to identify all definitions reported for detection of bone and bone marrow metastases on imaging in neuroblastoma to determine diagnostic accuracies of the most frequently used definitions for detection of bone and/or BM metastases on each imaging technique. Methods: We searched MEDLINE/PubMed (1945 to April 2013) and EMBASE/Ovid (1980 to April 2013). Full-text original studies were included if they reported definitions of bone and/or BM metastases on diagnostic imaging of children with suspected metastatic neuroblastoma. As reference standard for bone metastases bone scintigraphy was used and for bone marrow metastases bone marrow biopsies/aspirates. Methodological quality was assessed. Results: Of 403 identified studies (plus one relevant reference), 131 were assessed in full-text and 31 finally included, 23 described BM metastases and 18 bone metastases. No uniform definitions of bone and bone marrow metastases were reported for each imaging method. On MIBG scintigraphy bone metastases were mostly defined as “focal” and BM metastases as “diffuse” and on MRI both definitions were used for BM metastases. The diagnostic accuracy of different diagnostic methods to detect bone (reference test bone scintigraphy) or BM (reference test bone marrow biopsies/ trephines) metastases varied widely. Conclusion: No uniform definitions of bone and bone marrow metastases were reported for each imaging method and concerning the diagnostic accuracy no general conclusions could be drawn.

Highlights

  • Overall survival (OS) of high-risk neuroblastoma patients is about 40% despite intense multi-modality treatment [1,2,3,4], the addition of anti-GD2 therapy might improve this outcome [5]

  • Highrisk neuroblastoma is defined by the presence of distant metastases and/ or the presence of biological factors like amplification of the MYCN gene (MNA)

  • Ladenstein and co-workers reported an inferior outcome for patients with bone marrow metastases at initial diagnosis and an inferior, but not identical outcome for patients with bone and bone marrow metastases before mega-therapy [10]

Read more

Summary

Introduction

Overall survival (OS) of high-risk neuroblastoma patients is about 40% despite intense multi-modality treatment [1,2,3,4], the addition of anti-GD2 therapy might improve this outcome [5]. Because bone and bone marrow metastases are reported to be independent poor prognostic factors [6,7,8,9,10], it is necessary to have clear and uniform definitions of respectively bone metastases and bone marrow metastases, as well as a need of clear discrimination of both types of metastatic disease. In patients with metastatic disease younger than one year at diagnosis, the presence of bone metastases is reported to be associated with an inferior outcome [7]. In contrast to protocols for bone marrow involvement, no standardized protocols for the definition and differentiation of bone from bone marrow metastases on imaging are reported

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call